Yahoo Finance • last year

Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine

BRISBANE, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for peo... Full story

Yahoo Finance • last year

Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference

BRISBANE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for peo... Full story

Yahoo Finance • last year

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) and Encourages Investors to Contact the Firm

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) (“Day One”) on behalf of the company’s investors. Since February 2023, shares of Day One’... Full story

Yahoo Finance • last year

INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into Day One Biopharmaceuticals, Inc.; Urges Day One Stockholders to Contact Abbott Cooper Regarding Their Legal Rights

STAMFORD, Conn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”) on behalf of the Company’s investors. The investigation seeks to determi... Full story

Yahoo Finance • last year

Day One Reports Third Quarter 2023 Financial Results and Corporate Progress

NDA for tovorafenib in relapsed or progressive pLGG accepted for FDA priority review PDUFA target action date of April 30, 2024 BRISBANE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or... Full story

Yahoo Finance • last year

12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds

In this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. Click to skip past our discussion of the biotech space and straight to the 5 Best Small-Cap Biotech Stocks with Massiv... Full story

Yahoo Finance • last year

Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

BRISBANE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for peo... Full story

Yahoo Finance • last year

Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

Overall response rate (ORR) greater than 50% across three assessment criteria Median duration of tovorafenib treatment of 15.8 months as of June 5, 2023, with 66% of patients remaining on treatment FDA filing decision expected by mid-Nov... Full story

Yahoo Finance • last year

Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience

Day One receives an exclusive license to develop and commercialize small molecule drug candidates for pediatric and adult cancers with high unmet need Collaboration augments Day One’s portfolio of targeted therapies in oncology BRISBANE,... Full story

Yahoo Finance • 2 years ago

Day One Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

BRISBANE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with li... Full story

Yahoo Finance • 2 years ago

Day One Reports First Quarter 2023 Financial Results and Corporate Progress

FIREFLY-1 clinical abstract selected for oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Leadership team strengthened with executive appointments in clinical development and commercialization Pre... Full story

Yahoo Finance • 2 years ago

Day One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

New clinical data from registrational FIREFLY-1 study to be featured as an oral presentation Trial-in-progress poster from FIREFLY-2 andhealthcare resource use for pediatric low-grade glioma care poster to be presented Company to host co... Full story

Yahoo Finance • 2 years ago

Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress

BRISBANE, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-th... Full story

Yahoo Finance • 2 years ago

Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress

First patient dosed in pivotal Phase 3 FIREFLY-2/LOGGIC trial evaluating tovorafenib (DAY101) as a frontline therapy for patients newly diagnosed with pediatric low-grade glioma (pLGG) Reported topline data in January 2023 from ongoing, p... Full story

Yahoo Finance • 2 years ago

Day One to Participate in the Cowen 43rd Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages wi... Full story

Yahoo Finance • 2 years ago

Day One Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade Glioma

Overall response rate (ORR) of 64% and clinical benefit rate (CBR) of 91% in 69 heavily-pretreated, RANO-evaluable patients Median duration of 8.4 months on therapy as of September 28, 2022, with 77% of patients remaining on treatmentAddit... Full story

Yahoo Finance • 2 years ago

Day One to Present at the 41st Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages wi... Full story

Yahoo Finance • 2 years ago

Day One to Participate in the Piper Sandler 34th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages wi... Full story

Yahoo Finance • 2 years ago

Day One Announces Upcoming Presentations at 2022 Society for Neuro-Oncology Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages wi... Full story

Yahoo Finance • 2 years ago

Day One Reports Third Quarter 2022 Financial Results and Corporate Progress

Topline results for full pivotal FIREFLY-1 study population with tovorafenib (DAY101) in relapsed or progressive pediatric low-grade glioma (pLGG) are expected in the first quarter of 2023 Strengthened leadership team with key appointment... Full story